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esponsibility of InstAbstract RNA interference (RNAi) is useful for selective gene silencing. Cytochrome P450 3A4
(CYP3A4), which metabolizes approximately 50% of drugs in clinical use, plays an important role in drug
metabolism. In this study, we aimed to develop a short hairpin RNA (shRNA) to modulate CYP3A4
expression. Three new shRNAs (S1, S2 and S3) were designed to target the coding sequence (CDS) of
CYP3A4, cloned into a shRNA expression vector, and tested in different cells. The mixture of three
shRNAs produced optimal reduction (55%) in CYP3A4 CDS-luciferase activity in both CHL and
HEK293 cells. Endogenous CYP3A4 expression in HepG2 cells was decreased about 50% at both mRNA
and protein level after transfection of the mixture of three shRNAs. In contrast, CYP3A5 gene expression
was not altered by the shRNAs, supporting the selectivity of CYP3A4 shRNAs. In addition, HepG2 cells
transfected with CYP3A4 shRNAs were less sensitive to Ginkgolic acids, whose toxic metabolites are
produced by CYP3A4. These results demonstrate that vector-based shRNAs could modulate CYP3A4
expression in cells through their actions on CYP3A4 CDS, and CYP3A4 shRNAs may be utilized to
deﬁne the role of CYP3A4 in drug metabolism and toxicity.
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Table 2 IC50 of GA (15:1 and 17:1) in transfected HepG2
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RNA interference (RNAi) is an evolutionary conserved, cellular
defensive mechanism that down-regulates gene expression at the
post-transcriptional level1,2. RNAi mediated by small interfering
RNA (siRNA) causes sequence-speciﬁc mRNA degradation of the
targeted genes. This process involves multiple steps including the
assembly of siRNA into the RNA-induced silencing complex
(RISC), activation of the RISC, target recognition and binding, and
thus target cleavage3,4. There are different ways to generate
siRNAs for gene knockdown. The chemically synthesized siRNA
oligos are suitable for target veriﬁcation. The double strand RNAs
(dsRNAs) that are transcribed and digested in vitro are usually
used for the screening of siRNAs. The small hairpin RNAs
(shRNAs) expressed from plasmid can be used for stable gene
silencing and long-term studies. Therefore, vector-based expres-
sion of shRNA is increasingly used for delivery of siRNAs into
mammalian cells5,6.
The cytochrome P450 (CYP or P450) enzymes are encoded by 57
functional genes in humans; these enzymes catalyze the oxidative
metabolism of a vast array of chemicals including drugs, carcinogens
and toxins7. P450s are also involved in the biosynthesis or
biodegradation of many endogenous compounds such as steroids,
fatty acids and prostaglandins. Among them, CYP3A4 is the most
abundant isoform expressed in human adult liver (60% of total P450)
and intestine (70% of total P450), and plays an important role in
metabolizing approximately 50% of drugs in clinical use8,9. The
transcription of CYP3A4 is regulated by a number of nuclear
receptors such as pregnane X receptor (PXR)10,11 and constitutively
activated receptor (CAR)12. In contrast to the understanding of
nuclear receptor controlled transcriptional regulation of CYP3A4,
there are only limited studies on the post-transcriptional regulation of
CYP3A4 using RNAi at the 30-untranslated region13,14. Therefore, we
aimed to investigate the inhibitory effects of three new shRNA
expression vectors that target the coding region sequence (CDS) of
CYP3A4 in different cell models, and the consequent inﬂuence on
the sensitivity of cells to CYP3A4 substrates.cells.
Group IC50 (μmol/L)
GA 15:1 GA 17:1
Induced HepG2þshRNA plasmid 109778 101744
Induced HepG2þNegative plasmid 64728 527142. Materials and methods
2.1. Chemicals and reagents
Dulbecco0s modiﬁed Eagle's medium, fetal bovine serum, Trypsin,
Lipofectamine 2000 and TRIzol reagent were all purchased fromTable 1 Sequences and target of shRNA template oligonucleotides
Sequence and target of shRNA template oligonucleotide
Target sequence 1 AAAGTCGCCTCGAAGATAC
Sense strand 50–GATCCAGTCGCCTCGAA
Antisense strand 50–AGCTTAAAGTCGCCTCG
Position 773
Target sequence 2 AAACCACGAGCAGTGTTCT
Sense strand 50–GATCCACCACGAGCAGT
Antisense strand 50–AGCTTAAACCACGAGCA
Position 923
Target sequence 3 AAGCTATGCTCTTCACCGT
Sense strand 50–GATCCGCTATGCTCTTCA
Antisense strand 50–AGCTTAAGCTATGCTCT
Position 1191Invitrogen (Carlsbad, CA). RevertAidTM Reverse Transcriptase
was obtained from MBI Fermentas (Hanover, MD). Dual-
Luciferases Reporter Assay Kit was ordered from Promega
(Madison, WI). Plasmid miniprep kit was purchased from Qiagen
(Hilden, Germany). Oligonucleotide primers were synthesized by
Sangon Co. (Shanghai, China). Antibodies of rabbit anti-human
CYP3A4 were provided by AVIVA Systems Biology (California,
U.S.A.). Alexa Fluor 488 F[ab’]2 of goat anti-rabbit IgG [HþL]
was from MultiSciences Biotech Co., Ltd. (Hangzhou, China), and
horseradish peroxidase-labeled goat anti-rabbit IgG was obtained
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Rifampin
was purchased from MP Biomedicals Inc. (Eschwege, Germany).
2.2. Cell culture
Chinese hamster lung cells (CHL), Human Embryonic Kidney 293
cells (HEK293) and Human Hepatocellular Carcinoma cells
(HepG2), all purchased from ATCC, were cultured in DMEM
medium, supplemented with 10% FBS, 100 U/mL penicillin G
sodium, and 100 μg/mL streptomycin sulfates. Cell cultures were
grown at 37 1C in a humidiﬁed atmosphere of 5% CO2 and
95% air.
2.3. Design of hairpin siRNA template oligonucleotides and
construction of plasmids
Three hairpin siRNA (shRNA) template oligonucleotides (S1, S2
and S3), based on three different segments of the human CYP3A4
gene (GenBank accession no. NM_017460), were designed using
the siRNA Target Finder and Design Tool available at http://www.
ambion.com. The shRNA target sequences and the oligonucleo
tides designed to produce shRNAs are shown in Table 1. Two
complementary oligonucleotides that encoded a hairpin structure
with a 19-mer stem based on the mRNA target site were clonedused in this study.
AC
GATACACTTCAAGAGA GTGTATCTTCGAGGCGACTTTA-3'
AAGATACACTCTCTTGAAGTGTAT CTTCGAGGCGACTG-3'
CT
GTTCTCTTTCAAGAGAAGAGAAC ACTGCTCGTGGTTTA-3'
GTGTTCTCTTCTCTTGAAAGAGA ACACTGCTCGTGGTG-3'
GA
CCGTGATTCAAGAGATCACGGTGAAGAGCATAGCTTA-3'
TCACCGTGATCTCTTGAATCACGGTGAAGAGCATAGCG-3'
Siyun Xu et al.352into the pSilencer 4.1 CMV vector for siRNA expression. The
pSilencer 4.1 CMV vector contained the restriction sites of BamHI
and HindIII to ensure correct cloning into the linearized vector.
The oligonucleotides were annealed and cloned into the pSilencer
4.1 CMV vector. Then pSilencer vectors were sequenced with
universal primer to conﬁrm that the oligonucleotides were
connected to the desired site. A negative control vector was also
designed by scrambling the nucleotide sequence of the
gene-speciﬁc shRNA and conducting a blast search to ensure it
lacks homology to any other gene. CYP3A4 CDS (1512bp), which
was ampliﬁed from PGEMT-CYP3A4 CDS vector with primers
with the forward oligonucleotides 50–GCTCTAGAATGGC-
TCTCATCCCAGACTT-30 and reverse oligonucleotides 50–
GCGGCCGGCCTCAGGCTCCACTTACGGTGC-30, was cloned
into XbaI/FseI-digested pGL3 promoter vector (Promega).
CYP3A4 CDS was inserted downstream of the Fireﬂy luciferase
gene.
2.4. Luciferase assay
All the transfection experiments were conducted with Lipofecta-
mine 2000, following the manufacturer's instructions. Brieﬂy,
CHL cells were transiently cotransfected with pGL3/CYP3A4
CDS-luciferase reporter plasmid (0.1 μg) and shRNA plasmid or
pS-NC plasmid (0.4 μg), together with pRL-TK plasmid (0.01 μg)
which expresses Renilla luciferase. Luciferase activities were
assayed 48 h after transfection using the Dual-Luciferase Reporter
Assay System (Promega, Madison, WI). Likewise, HEK293 cells
were cotransfected with pGL3/CYP3A4 CDS-luciferase reporter
plasmid (0.1 μg) and shRNA plasmid mixture or pS-NC plasmid
(0.4 μg). Fireﬂy luciferase activity was determined and normalized
against Renilla luciferase activity and compared among different
treatments15.
2.5. RT-PCR
Speciﬁc PCR primer pairs for human CYP3A4 and CYP3A5 gene
were derived from publication14. HepG2 cells treated with
rifampicin were seeded in 24-well plates at a density of 2 105
cells per well and incubated overnight. The cells were transfected
with shRNA plasmid or pS-NC plasmid. Total RNA was isolated
from cultured cells using the TRIzol reagent following the
instructions from the manufacturer 48 h later. The purity and
integrity of the RNA was conﬁrmed using an ultraviolet spectro-
meter before use. The RT reaction was carried out in a total
volume of 20 μL, containing 2 μg of RNA, 50 μg/L Oligo(dT)18
(Sangon Co.), 10 mmol/L dNTP mix, M-MLV 5 reaction
buffer, 40 U of RNase inhibitor, and 200 U of M-MLV at 42 1C
for 1 h. PCR was performed by using the CYP3A4 primers
50–AAATCTGAGGCGGGAAGC-30 (forward; F) and 50–
TTGGGATGAGGAATGGAAAG-30 (reverse; R)14; CYP3A5 pri-
mers 50–ATGGAAAAATGTGGGGAACG-30 (forward; F) and
50–CGCTGGTGAAGGTTGGAGAC-30 (reverse; R)14,16. The
PCR reaction was conducted in a volume of 20 μL containing
0.3 μL of Taq enzyme (2.5 U/μL), 2 μL of dNTP at 2 mmol/L,
4 μL of RT product, 1 μL of each primer at 10 pmol, 2 μL of 10
 PCR reaction buffer. The PCR conditions were as follows:
95 1C for 2 min; 30 cycles of 95 1C for 45 s, 55 1C for 45 s and
72 1C for 45 s; followed by incubation at 72 1C for 10 min. RT-
PCR was also performed using primers for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) gene messages as a control.Five microliters of the ampliﬁed products were resolved by
electrophoresis in a 1.0% agarose gel, and band intensities were
determined by QuantityOne analysis software (Bio-Rad Labora-
tories, Segrate, Italy).
2.6. Immunoﬂuorescence chemistry
HEK293 cells were seeded in 24-well plates at a density of 5 104
cells per well and incubated overnight. The cells were transiently
cotransfected with pGL3/CYP3A4 CDS-luciferase reporter plas-
mid (0.1 μg) and shRNA plasmid or pS-NC plasmid (0.4 μg). 48 h
later, the cells were ﬁxed with 4% paraformaldehyde in 0.1 mol/L
phosphate buffer (pH 7.4). Then the cells were permeabilized with
in 0.1% Triton X-100 plus 1% BSA in PBS/pH 7.3 for 10 min on
ice, and blocked for 30 min in 1% BSA-PBS. The cells were
incubated with primary antibody against CYP3A4 (AVIVA
Systems Biology, California, USA) diluted in 1% BSA-PBS at
4 1C overnight and washed three times with PBS. Then the cells
were incubated with secondary antibody (DyLight 488 conjugated
of Goat Anti-rabbit IgG, MultiSciences Biotech Co., Ltd., Hang-
zhou, China) diluted in 1% BSA-PBS for 2 h at room temperature,
and washed three times with PBS17. The antibody distribution was
visualized with a DMI 3000B microscope (Leica), and images
were acquired using Leica FW4000 version 1.2.1 software.
2.7. Western blot analysis
HepG2 cells treated with rifampicin or DMSO were seeded in 6-
well plates at a density of 5 105 cells per well and incubated
overnight. Cells were harvested at 48 h after transfection with
10 μL Lipofectamine 2000 and shRNA plasmid or pS-NC plasmid.
The cell lysates were prepared with a buffer containing 50 mmol/L
Tris- HCl, pH 7.5, 100 mmol/L NaCl, 5 mmol/L EDTA, 1% (v/v)
Triton X-100, 1 mmol/L NaF, 1 mmol/L Na3VO4, 0.2 mmol/L
phenylmethylsulfonyl ﬂuoride, 10 μg/mL leupeptin, and 10 μg/mL
aprotinin. Lysates were centrifuged at 12,000 g at 4 1C for
10 min14. Protein concentrations were determined using the BCA
Protein Assay Kit. Twenty-ﬁve μg of protein were separated on
7.5% SDS-polyacrylamide gels and electrophoretically transferred
onto nitrocellulose membranes. The membranes were blotted with
antibodies against antibodies of rabbit anti-human CYP3A4
(AVIVA Systems Biology, California, USA). To assure equivalent
protein loading, the membranes were also incubated with mouse
anti-human GAPDH monoclonal antibodies and subsequently with
a corresponding horseradish peroxidase-conjugated second anti-
body IgG (Santa Cruz Biotechnology, Inc., Santa Cruz, CA). The
proteins were visualized with chemiluminescence detection kit for
HRP (Biological Industries, Kibbutz Beit-Haemek, Israel). Images
were acquired and densitometric analyses were conducted using
QuantityOne analysis software (Bio-Rad Laboratories, Segrate,
Italy).
2.8. Cytotoxicity assay
Cell viability was determined by MTT method. Five thousand
cells/well were seeded in 96-well plates (Costar, Ann Arbor, MI).
The next day, the HepG2 cells treated with rifampicin or DMSO
were transfected with shRNA plasmid (0.2 μg) or pS-NC plasmid
(0.2 μg). Drugs were added at increasing concentrations 48 h after
transfection. Control cells were treated with an equal concentration
of vehicle alone. 24 h later, the drug-containing medium was
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(5 mg/mL) were added to each well. After incubation for 4 h at
37 1C, the supernatant was removed, and 150 μL of DMSO was
added. The plates were vigorously shaken for 10 min to solubilize the
MTT-formazan product. The absorbance was read using SpectraMax
M2 reader (Molecular Devices, California, U.S.A) at a wavelength of
570 nm. Vehicle-treated cells were assigned a value of 100%13,15.
Each experiment was performed in triplicate wells for each drug
concentration and carried out independently three times in different
days. The cytotoxicity was evaluated with reference to the IC50 value.
IC50 values were calculated from dose-response curves (i.e., cell
survival versus drug concentration) obtained in multireplicated
experiments using GraphPad Prism 5.0.
2.9. Statistical analysis
All values were expressed as mean7SD. Statistical analyses were
conducted using one-way ANOVA with Dunnett's posttest, and
multiple variances were analyzed by two-way ANOVA (GraphPad
Prism). P values less than 0.05 were considered as statistically
signiﬁcant.Figure 1 CYP3A4 CDS-luciferase activities are reduced by indivi-
dual or combined shRNAs in CHL cells. (A) CHL cells co-transfected
with CYP3A4 CDS-luciferase reporter, pRL-TK and different shRNA
expression plasmids showed 20%–30% lower luciferase activities,
compared to cells transfected with the pS-NC plasmid. (B) CHL cells
transfected with CYP3A4 CDS-luciferase reporter, pRL-TK and
different combinations of shRNA expression plasmids showed 40%–
50% lower luciferase activities, compared to cells transfected with the
pS-NC plasmid. Fireﬂy luciferase activity was normalized to corre-
sponding Renilla luciferase activity, and the control group was set as
100%. *Po0.05; ***Po0.001 compared to the corresponding control
(n¼3 in each group, which refers to the number of independent
transfection samples in a representative experiment).3. Results
3.1. CYP3A4 CDS can be targeted by individual or combined
shRNAs
To test if CYP3A4 CDS can be targeted by siRNA, three shRNA
constructs (S1, S2 and S3) were designed to act on different
regions of the CYP3A4 mRNA sequence (Table 1). CHL cells
were transiently cotransfected with CYP3A4 CDS-luciferase
reporter plasmid and shRNA or pS-NC plasmid. Results found
slight (o 30%) to no decrease in CYP3A4 CDS-luciferase activity
by individual shRNAs (Fig. 1A). Interestingly, use of combined
shRNAs led to signiﬁcantly increased suppression (up to 55%) of
CYP3A4 CDS-luciferase activity (Fig. 1B). Therefore, the mixture
of three shRNAs (named S1þS2þS3; at a ratio of 1:1:1) was
utilized to assess the capacity of RNAi on CYP3A4 gene
expression in the following studies.
HEK293 cells were further used to evaluate the efﬁciency of
CYP3A4 shRNAs, following a transient cotransfection with pGL3/
CYP3A4 CDS-luciferase reporter plasmid and shRNA or pS-NC
plasmid. Luciferase reporter assay showed that the luciferase
activity decreased by 5372.2% in the HEK293 cells by the
shRNAs mixture (Fig. 2A). In addition, our immunoﬂuorescence
study demonstrated that CYP3A4 protein level was decreased
dramatically in HEK293 cells transfected with the shRNA mixture
(Fig. 2B) These results indicate that designated shRNAs are able to
target CYP3A4 CDS sequences to induce gene suppression.
3.2. Expression of endogenous CYP3A4 mRNA is selectively
reduced by combined shRNAs in HepG2 cells
To investigate the impact of shRNAs on endogenous CYP3A4
expression, we utilized the human hepatocellular carcinoma cell
line HepG2 which is an in vitro model system for the study on
human CYP gene regulation. Since the basal level of CYP3A4 is
low in HepG2 cells, we ﬁrst employed rifampicin to induce
CYP3A4 expression. The treatment of rifampicin (50 μmol/L)
increased CYP3A4 mRNA level by 2-fold in HepG2 cells(Fig. 3A). Following the induction of CYP3A4 by rifampicin,
the shRNA plasmid mixture was revealed to reduce CYP3A4
mRNA expression by 35715.9% and 47.5713.8% in HepG2
cells after a 24 h and 48 h treatment, respectively, as demonstrated
by the RT-PCR (Figs. 3B and 3C) analyses.
Because CYP3A4 and CYP3A5 genes exhibit 84% similarity in
sequence, we further evaluated the selectivity of CYP3A4
shRNAs. As expected, treatment of HepG2 cells with shRNA
plasmid mixture did not alter the expression of CYP3A5 mRNA
expression (Fig. 3D). Together, these results indicate that the
shRNA mixture selectively suppresses endogenous CYP3A4
mRNA expression in HepG2 cells.
3.3. Expression of endogenous CYP3A4 protein is suppressed by
combined shRNAs in HepG2 cells
Immunoblot analyses were conducted with CYP3A4-selective
antibody to examine whether shRNAs reduce CYP3A4 protein
expression. The data (Fig. 4) showed that CYP3A4 protein level
was reduced about 50% in HepG2 cells after transfection with the
mixture of three shRNAs. This was associated with a reduction of
CYP3A4 mRNA expression (Fig. 3B). These results suggest that
shRNAs effectively repress CYP3A4 protein expression in HepG2
cells through the down-regulation of CYP3A4 mRNA expression.
Figure 2 Combined shRNAs are effective in targeting CYP3A4 CDS in HEK293 cells. (A) HEK293 cells transfected with CYP3A4 CDS-
luciferase reporter and three shRNA expression plasmids showed about 50% lower luciferase activities, compared to cells transfected with the pS-NC
plasmid. ***Po0.001 compared to the control (n¼3 in each group, which refers to the number of independent transfection samples in a representative
experiment). (B) Fluorescent microscopic pictures of CYP3A4 expression in HEK293 cells at 48 h after transient transfection with CYP3A4 CDS-
luciferase reporter plasmid alone (CYP3A4), along with control plasmid (pS-NC) or three shRNA expression plasmids (S1þS2þS3).
Figure 3 The mixture of three shRNA plasmids inhibits endogenous CYP3A4 mRNA expression in HepG2 cells. (A) CYP3A4 mRNA
expression was elevated 2-fold in HepG2 cells by rifampicin (50 μmol/L for 48 h), as determined by RT-PCR analysis. (B) and (C) The shRNA
expression plasmid mixture suppressed CYP3A4 mRNA levels in HepG2 cells. (D) The shRNA expression plasmid mixture did not change
CYP3A5 mRNA expression in the HepG2 cells. Relative CYP3A4/5 mRNA expression level was normalized to corresponding GAPDH mRNA
level, and the control group was set as 100%. ***Po0.001, compared to the vehicle control. n¼3 in each group, which refers to the number of
independent transfection samples in a representative experiment.
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Figure 4 Expression of endogenous CYP3A4 protein is suppressed
by combined shRNAs in HepG2 cells. CYP3A4 protein expression
(A) in HepG2 cells (treated with rifampicin) was suppressed by about
50% (B) after the transfection with the shRNA expression plasmid
mixture, compared to pS-NC control plasmid. CYP3A4 protein ex-
pression level was normalized to corresponding GAPDH level in
HepG2 cells, and control group was set as 100%. ***Po0.001, com-
pared to the negative control (n¼3 in each group, which refers to the
number of independent transfection samples in a representative experiment).
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Ginkgolic acid (15:1) (GA (15:1)) and ginkgolic acid (17:1) (GA
(17:1)), two substrates metabolized by CYP3A4 to more toxic
metabolites18,19, were used to examine the impact of CYP3A4
shRNAs on chemosensitivity. Treatment with GA (15:1) or GA
(17:1) (at 5 to 100 μmol/L) for 24 h led to a signiﬁcant cytotoxicity
in HepG2 cells when CYP3A4 was induced by rifampicin20,21.
Interestingly, the transfection with shRNA plasmid mixture
increased the resistance of HepG2 cells to GA (15:1) and GA
(17:1), as manifested by a higher IC50 value (109 mmol/L and
101 mmol/L, respectively), compared to the transfection with
control plasmid (64 μmol/L and 52 μmol/L, respectively)
(Fig. 5). A lower cytotoxicity is presumably due to the reduction
of CYP3A4 expression by shRNAs (Fig. 4). Take together, these
results indicate that shRNA plasmid mixture not only reduces
CYP3A4 expression but also affected the sensitivity of cells to
drugs metabolized by CYP3A4.4. Discussion
The cytochrome P450 enzymes (CYP450), which are found in all
living organisms, play a predominant role in metabolism. In
humans they constitute at least 57 different proteins and are found
mainly in the liver. CYPs are the major enzymes involved in drugmetabolism and bioactivation and account for about 75% of the
total number of different metabolic reactions. CYP3A4 is the most
abundant CYP450 in human liver and intestine, and contributes to
the metabolism of various drugs9. As we know, chemical
inhibitors or inhibitory antibodies to CYP3A4 are less speciﬁc
and always exhibit cross-reactivity between CYP3A4 and other
enzymes, especially CYP3A5, which possibly complicates inter-
actions with the substrates22. So far, a number of studies using
antisense approach to regulate CYP450 have been published in the
past decade, which has made great contribution to our under-
standing of these enzymes. Although the antisense oligonucleo-
tides have received increasing attention, this technology still has
formidable problems. In most cases, antisense oligonucleotides
degrade rapidly, therefore their effects are temporary and the
potency is low23–25. Until recently, some progress has been made
on the inhibition of CYP450s using RNA interference. The studies
by Pan et al.15 indicated that microRNA-27b (miR-27b) and
mouse microRNA-298 (mmu-miR-298) could directly act on the
30–UTR of CYP3A4. In addition, three different constructs to
produce shRNA molecules have been designed and investigated
by Chen et al.14.
In the present study, the vector-based RNAi technology to
express shRNA molecules was adopted. As mentioned above, this
gene silencing approach has been conﬁrmed to inhibit CYP3A4
expression in Chen et al.'s study. In their research, three
oligonucleotides (3A4I, II, and III) were designed, and only
CYP3A4III which targeted the 30–UTR of CYP3A4 (position in
gene sequence is 1698–1719) signiﬁcantly reduced CYP3A4
expression at both mRNA and protein levels, while the other
two did not generate obvious inhibitory effects on CYP3A4
expression. As we know, the siRNAs are usually designed to act
on the CDS of target genes in order to avoid the interference of
regulatory proteins in 50–UTR or 30–UTR. Furthermore, this type
of siRNAs can be applied to the engineering cell lines which
transfected either with the CDS or the full length cDNA of target
gene. Therefore, the efﬁcacy of CDS-targeted siRNAs in suppres-
sing CYP3A4 gene expression was important to investigate. For
these reasons, according to siRNA design guidelines and the
CYP3A4 gene sequence, we chose three novel sites targeting the
coding regions whose position in gene sequence were 773–794,
923–944 and 1191–1212, respectively. Up to now, these sites have
never been reported and their functions were investigated from
three aspects.
We ﬁrst determined the effective pattern of shRNA expression
vectors. Unlike CYP3A4III, which has been selected as the most
effective shRNA among the three oligonucleotides in Chen et al.'s
research, none of the three kinds of shRNA expression plasmid
targeting the coding regions exhibited obvious inhibitory function
in CHL cells and HEK293 cells. However, when they were mixed
together at a ratio of 1:1:1, CYP3A4 gene was reduced signiﬁ-
cantly (450%). These results suggested that the combined
shRNAs could be used in further investigation.
The above speculation was derived from the impact of shRNAs
on exogenous CYP3A4 which was obtained from recombinant
plasmid. In this state, the 30–UTR of CYP3A4 gene was excluded.
As we know, the same siRNA may exhibit great discrepancy of
inhibition activity in different conditions. So whether this mixture
system possessed similar inhibitory efﬁciency for endogenous
CYP3A4 gene was worthy exploring. The human hepatocellular
carcinoma cell line HepG2 is an in vitro model system for the
study on human CYP gene regulation. Although HepG2 cell line
expresses many of the hepatocyte-speciﬁc metabolic enzymes that
Figure 5 CYP3A4 shRNAs alter the chemosensitivity of cells. Transfection of HepG2 cells with CYP3A4 shRNAs reduces the sensitivity to GA
(15:1) or GA (17:1), compared to the cells transfected with control plasmid. Cytotoxicity was determined by the MTT assay. The inhibition rate
relative to the control (0%) was calculated for each concentration of drug, and the IC50 value was estimated by ﬁtting the data to a Hill
equation (Table 2).
Siyun Xu et al.356characterize the liver, it is seldom adopted because the basal
expression level of CYP450s was usually low. In this study, the
endogenous CYP3A4 mRNA level was obviously up-regulated by
rifampicin, which provided an ideal cell model for CYP3A4
silencing investigations both on gene expression and metabolic
activity. RT-PCR and western blot analyses showed that CYP3A4
was suppressed by approximately 50% at both gene and protein
levels when CYP3A4 was expressed endogenously. As expected,
the inhibition rate was consistent between exogenous and endo-
genous cell models. Despite the component of the shRNAs
mixture was more complicated than the single one, the suppression
ratio of CYP3A4 gene remained stable. It was probably because all
of the three shRNA constructs were constructed using the same
expression vector, so their mixture was homogeneous, possibly
suppressing CYP3A4 gene expression in an additive way. As a
result, such combined shRNAs could be regarded as a system that
owned three different target sites of CYP3A4 coding region.
Furthermore, our study demonstrated that the mixture of shRNA
expression vectors did not alter CYP3A5 gene expression which
exhibited 84% homology with CYP3A4 and similar gene regula-
tion in hepatocytes at mRNA level in HepG2 cells treated with
rifampicin. This result revealed that the suppression of CYP3A4
gene by the mixture system was speciﬁc and targeted CYP3A4
mRNA only, which further indicated that such shRNA mixture
might become a powerful approach for studying CYP3A4 func-
tion. For this reason, we applied the mixture of shRNA expression
vectors in drug development.
The cytotoxicity assay by MTT method has been applied and
proved to be efﬁcient in down-regulating the metabolic activity of
CYP450s19. GA (15:1) and GA (17:1) are major compounds in
ginkgolic acid prepared by our lab and have been proved that theactivation of their cytocidal activity requires CYP3A419. Our data
demonstrated that shRNA-transfected HepG2 cells were signiﬁ-
cantly resistant to the drug because of the suppression of CYP3A4
by shRNA expression vectors. As a result, the activation of GA
(15:1) and GA (17:1) was reduced. Our study provided conﬁrma-
tory evidence that CYP3A4 is the major enzyme metabolizing GA
(15:1) and GA (17:1). Thus, the use of such shRNA expression
vectors targeted the coding regions has important clinical sig-
niﬁcance because of CYP3A4's important role in manipulating the
metabolic fate of existing drugs and the potential substrates.
Furthermore, this strategy in combination with other established
inhibitors may reduce individual differences in drug metabolism,
thereby attenuating organ toxicity. Therefore, the response to
therapy will be more predictable26,27.
To sum up, although the shRNA vector-mediated RNAi for
CYP3A4 has been reported by Chen et al., the shRNAs system in
the present study still has its own characteristics. First, the three
shRNAs expression vectors were designated to the CDS of
CYP3A4 which have never been reported. They can be applied
to the engineering cell lines transfected either with the CDS or the
full length cDNA of CYP3A4 gene, or applied to cell lines which
express CYP3A4 endogenously. Therefore, their application range
was more extensive. Second, the identiﬁcation of improved
efﬁciency of mixed shRNAs in silencing CYP3A4 is a very
interesting discovery. It may be an additive effect, and the
mechanism requires thorough investigation in order to provide
alternative strategy for gene silencing. This seems especially true
when single siRNA is difﬁcult to screen. According to the
literature, some vectors which can express multiple shRNAs have
been provided (e.g., pcDNA6.2-GW/miR)28. Therefore, the multi-
silencing construct could be used in investigations where a gene
Three new shRNA expression vectors targeting the CYP3A4 coding sequence 357with several target sites or where knockdown of multiple genes
was required29. Such approach may be adopted to avoid carrying
out multiple individual shRNA expression vectors and improve
transfection efﬁciency in further research in this area. Third, even
though the CYP3A4 gene was not knocked down completely, the
activity of CYP3A4 was altered signiﬁcantly. Thus this shRNAs
mixture can be regarded as a speciﬁc inhibitor of CYP3A4, which
can be utilized to screen the substrates or introducer of CYP3A4.5. Conclusions
We have achieved speciﬁc reduction of CYP3A4 expression using
a set of three novel shRNAs that target the CYP3A4 coding
region. Our studies demonstrate that a mixture of multiple shRNAs
can be used to improve the effectiveness of shRNA-mediated
silencing of CYP3A4 expression, and that the usage of RNAi is
promising as an approach to inhibit the expression and activity of
this important drug metabolism enzyme.
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